Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
perifosine + imatinib
- Development stage
- Unknown
- Lead developer
- Akebia Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Perifosine + imatinib** is an oral combination of two small molecule agents: *perifosine*, an alkylphospholipid Akt inhibitor, and *imatinib*, a kinase inhibitor targeting BCR-ABL, KIT, and PDGFRA. This combination has been studied primarily in patients with gastrointestinal stromal tumor (GIST) who have shown resistance or progression on imatinib monotherapy. The rationale for the combination is that perifosine’s inhibition of the Akt pathway could overcome or delay acquired resistance to imatinib by inhibiting downstream survival signals in tumors with KIT mutations. Clinical studies have assessed the safety and efficacy of the combination, with the main reported toxicities being gastrointestinal, hepatic, and potential ocular (ulcerative keratitis) adverse effects.
- Other names
- perifosine + Gleevec
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)
Beyond the preview
Go deeper on perifosine + imatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on perifosine + imatinib.